Ian Scanlon

710 total citations
9 papers, 579 citations indexed

About

Ian Scanlon is a scholar working on Molecular Biology, Genetics and Biotechnology. According to data from OpenAlex, Ian Scanlon has authored 9 papers receiving a total of 579 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 5 papers in Genetics and 4 papers in Biotechnology. Recurrent topics in Ian Scanlon's work include Virus-based gene therapy research (5 papers), Cancer Research and Treatments (4 papers) and Click Chemistry and Applications (3 papers). Ian Scanlon is often cited by papers focused on Virus-based gene therapy research (5 papers), Cancer Research and Treatments (4 papers) and Click Chemistry and Applications (3 papers). Ian Scanlon collaborates with scholars based in United Kingdom and United States. Ian Scanlon's co-authors include Caroline J. Springer, Frank Friedlos, Richard Marais, Lesley Ogilvie, Douglas Hedley, Dan Niculescu‐Duvaz, Jan Martin, Maria Karasarides, Christopher J. Marshall and Antonio Chiloeches and has published in prestigious journals such as Cancer Research, Oncogene and Journal of Medicinal Chemistry.

In The Last Decade

Ian Scanlon

9 papers receiving 562 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ian Scanlon United Kingdom	8	450	226	92	88	87	9	579
Jan Martin United Kingdom	6	843 1.9×	431 1.9×	74 0.8×	146 1.7×	81 0.9×	7	1.0k
Ying-Nan P. Chen United States	6	741 1.6×	338 1.5×	55 0.6×	27 0.3×	46 0.5×	7	892
Kristine M. Kim South Korea	13	650 1.4×	376 1.7×	38 0.4×	38 0.4×	87 1.0×	24	1.0k
Vladimir Khazak United States	20	985 2.2×	298 1.3×	68 0.7×	56 0.6×	67 0.8×	34	1.2k
MV Blagosklonny United States	9	547 1.2×	185 0.8×	54 0.6×	24 0.3×	40 0.5×	9	773
Kanda Sangthongpitag Singapore	15	629 1.4×	245 1.1×	48 0.5×	30 0.3×	76 0.9×	25	827
Vishal Pendharkar Singapore	12	714 1.6×	270 1.2×	62 0.7×	23 0.3×	137 1.6×	15	1.0k
O.-G. Issinger Germany	14	648 1.4×	155 0.7×	87 0.9×	15 0.2×	56 0.6×	18	762
Lesley Ogilvie United Kingdom	13	978 2.2×	488 2.2×	162 1.8×	168 1.9×	123 1.4×	13	1.2k
Josh Bliesath United States	6	1.3k 2.9×	284 1.3×	44 0.5×	29 0.3×	106 1.2×	13	1.5k

Countries citing papers authored by Ian Scanlon

Since Specialization

Citations

This map shows the geographic impact of Ian Scanlon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian Scanlon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian Scanlon more than expected).

Fields of papers citing papers by Ian Scanlon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian Scanlon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian Scanlon. The network helps show where Ian Scanlon may publish in the future.

Co-authorship network of co-authors of Ian Scanlon

This figure shows the co-authorship network connecting the top 25 collaborators of Ian Scanlon. A scholar is included among the top collaborators of Ian Scanlon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian Scanlon. Ian Scanlon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Niculescu‐Duvaz, Ion, Esteban Román, Steven R. Whittaker, et al.. (2008). Novel Inhibitors of the v-raf Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) Based on a 2,6-Disubstituted Pyrazine Scaffold. Journal of Medicinal Chemistry. 51(11). 3261–3274. 30 indexed citations

Schepelmann, Silke, Lesley Ogilvie, Douglas Hedley, et al.. (2007). Suicide Gene Therapy of Human Colon Carcinoma Xenografts Using an Armed Oncolytic Adenovirus Expressing Carboxypeptidase G2. Cancer Research. 67(10). 4949–4955. 50 indexed citations

Schepelmann, Silke, Paul L. Hallenbeck, Lesley Ogilvie, et al.. (2005). Systemic Gene-Directed Enzyme Prodrug Therapy of Hepatocellular Carcinoma Using a Targeted Adenovirus Armed with Carboxypeptidase G2. Cancer Research. 65(12). 5003–5008. 27 indexed citations

Niculescu‐Duvaz, Ion, Esteban Román, Steven R. Whittaker, et al.. (2005). Novel Inhibitors of B-RAF Based on a Disubstituted Pyrazine Scaffold. Generation of a Nanomolar Lead. Journal of Medicinal Chemistry. 49(1). 407–416. 36 indexed citations

Davies, Lawrence, Frank Friedlos, Douglas Hedley, et al.. (2005). Novel Fluorinated Prodrugs for Activation by Carboxypeptidase G2 Showing Good in Vivo Antitumor Activity in Gene-Directed Enzyme Prodrug Therapy. Journal of Medicinal Chemistry. 48(16). 5321–5328. 23 indexed citations

Niculescu‐Duvaz, Dan, Ian Scanlon, Ion Niculescu‐Duvaz, & Caroline J. Springer. (2005). A higher yielding synthesis of the clinical prodrug ZD2767P using di-protected 4-[N,N-bis(2-hydroxyethyl)amino]phenyl chloroformate. Tetrahedron Letters. 46(40). 6919–6922. 3 indexed citations

Karasarides, Maria, Antonio Chiloeches, Robert Hayward, et al.. (2004). B-RAF is a therapeutic target in melanoma. Oncogene. 23(37). 6292–6298. 360 indexed citations

Niculescu‐Duvaz, Ion, Ian Scanlon, Dan Niculescu‐Duvaz, et al.. (2004). Significant Differences in Biological Parameters between Prodrugs Cleavable by Carboxypeptidase G2 That Generate 3,5-Difluoro-phenol and -aniline Nitrogen Mustards in Gene-Directed Enzyme Prodrug Therapy Systems. Journal of Medicinal Chemistry. 47(10). 2651–2658. 18 indexed citations

Friedlos, Frank, Lawrence Davies, Ian Scanlon, et al.. (2002). Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models.. PubMed. 62(6). 1724–9. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact